Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Raises $18.2M in Private Stock Sale

NEW YORK (GenomeWeb News) – Fluidigm has raised $18.2 million through the private placement of an undisclosed number of shares, according to a filing with the US Securities and Exchange Commission.

The South San Francisco, Calif.-based firm is seeking to raise up to a total of $24.1 million from the offering, according to the SEC filing.

A Fluidigm spokesman confirmed the amount of money raised so far, but he could not provide any further details at this time.

Fluidigm President and CEO Gajus Worthington recently told GenomeWeb Daily News that the company intends to quadruple the size of its US sales staff to 60 people over the next two years. "It's clear that the market is there, the business is there, and now we really need to hire a large number of experienced sales operations folks in North America," he told GWDN.

The company had planned to go public last year, but was thwarted by the economic downturn and the stock market's nosedive in the fall of 2008. At the time, it had hoped to raise as much as $82 million to support its R&D and commercialization efforts.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.